Indexed in

License and use

Citations

Cited 2 times in

Altmetrics

Grant support

This study was supported by grants PI22/01595 and PI19/00694 from the Spanish Ministry of Economy and Competitiveness, CIBERCV, and Gobierno de Aragon B-14. These projects are co-funded by Instituto de Salud Carlos III and the European Regional Development Fund (ERDF) of the European Union, "A Way to Make Europe."

Analysis of institutional authors

Share

PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention

Publicated to:Lipids In Health And Disease. 23 (1): 290- - 2024-09-10 23(1), DOI: 10.1186/s12944-024-02283-x

Authors: Marco-Benedi, Victoria; Sanchez-Hernandez, Rosa M; Diaz, Jose Luis; Jarauta, Estibaliz; Suarez-Tembra, Manuel; Pinto, Xavier; Morillas, Carlos; Plana, Nuria; Pedro-Botet, Juan; Civeira, Fernando

Affiliations

Abstract

BackgroundProprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have represented an important change in the management of hypercholesterolemia, although, until now, they have barely been used. Without PCSK9i, many patients with atherosclerotic cardiovascular disease (CVD) or those at very high risk do not reach their therapeutic LDLc objectives.ObjectiveThe analysis aimed to examine the clinical and biochemical characteristics of subjects receiving PCSK9i treatment in the Dyslipidemia Registry of the Spanish Atherosclerosis Society.MethodsAll consecutive subjects aged >= 18 years from different Lipid Units included in the Dyslipidemia Registry of the SEA were analyzed. Inclusion criteria consisted of unrelated patients aged >= 18 at the time of inclusion with hypercholesterolemia (LDL-C >= 130 mg/dL or non-HDL-C >= 160 mg/dL after the exclusion of secondary causes) who were studied for at least two years after inclusion. Participants' baseline and final visit clinical and biochemical characteristics were analyzed based on whether they were on primary or secondary prevention and whether they were taking PCSK9i at the end of follow-up.ResultsEight hundred twenty-nine patients were analyzed, 7014 patients in primary prevention and 1281 in secondary prevention at baseline. 4127 subjects completed the required follow-up for the final analysis. The median follow-up duration was 7 years (IQR 3.0-10.0). Five hundred patients (12.1%) were taking PCSK9i at the end of the follow-up. The percentage of PCSK9i use reached 35.6% (n = 201) and 8.7% (n = 318) in subjects with and without CVD, respectively. Subjects on PCSK9i and oral lipid-lowering agents with and without CVD achieved LDLc reductions of 80.3% and 75.1%, respectively, concerning concentrations without lipid-lowering drugs. Factors associated with PCSK9i use included increasing age, LDLc without lipid-lowering drugs and the Dutch Lipid Clinic Network (DLCN) score. However, hypertension, diabetes, smoking, and LDLc after oral lipid-lowering drugs were not independent factors associated with PCSK9i prescription. In subjects with CVD, the use of PCSK9i was higher in men than in women (an odds ratio of 1.613, P = 0.048).ConclusionsApproximately one-third of CVD patients received PCSK9i at the end of follow-up. The use of PCSK9i was more focused on baseline LDLc concentrations rather than on CVD risk. Women received less PCSK9i in secondary prevention compared to men.

Keywords